CytomX Therapeutics Profile

USD 0.04  0.16%

Acquisition by Charles Fuchs of 14000 shares of CytomX Therapeutics subject to Rule 16b-3

CytomX Therapeutics insider trading alert for grant of stock option (right to buy) by Charles Fuchs, the corporate stakeholder, on June 15, 2018. This event was filed by Cytomx Therapeutics Inc with SEC on 2018-06-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

CytomX Therapeutics Summary

CytomX Therapeutics (CTMX) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 92 people. CytomX Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 971.6 M. CytomX Therapeutics conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 38.96 M outstanding shares of which 1.75 M shares are currently shorted by private and institutional investors with about 5.23 trading days to cover. CytomX Therapeutics currently holds about 361.48 M in cash with 174.85 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.28.
Check CytomX Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 24.5HorizonTargetOdds Above 24.5
41.57%30 days 24.50 58.19%
Based on normal probability distribution, the odds of CytomX Therapeutics to move above current price in 30 days from now is about 58.19% (This CytomX Therapeutics probability density function shows the probability of CytomX Therapeutics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares5.8 M164.8 M
Price T Rowe Associates IncCommon Shares2.9 M81.7 M
View CytomX Therapeutics Diagnostics

Selected CytomX Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

CytomX Therapeutics Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for CytomX Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. CytomX Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 92 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameCytomX Therapeutics
President CEO, DirectorSean McCarthyView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address151 Oyster Point Boulevard
CIK Number01501989.0
IndustryPharmaceutical Products
Contact Number650 515 3185
CurrencyUSD - US Dollar


CytomX Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
CytomX Therapeutics current and past analyst recommendations published by number of research institutions as well as average analyst consensus
CytomX Therapeutics Analyst Advice  


CytomX Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.45March 6, 2017
CytomX Therapeutics normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


CytomX Therapeutics Corporate Directors
Matthew Young Independent Director, MBA
Marion McCourt Director
Charles Fuchs Director
Check also Trending Equities. Please also try Money Flow Index module to determine momentum by analyzing money flow index and other technical indicators.